Lorlatinib manufacturer

Lorlatinib is a third-generation ALK tyrosine kinase inhibitor (TKI) developed and produced by Pfizer of the United States. As one of the world's leading pharmaceutical companies, Pfizer focuses on oncology, cardiovascular disease, immunology and other fields, and its innovative drugs have widespread influence around the world.

Manufacturer Profile

1.Pfizer Inc. (Pfizer Inc.): Pfizer is headquartered in New York, USA and is one of the world's largest pharmaceutical companies. Lorlatinib was developed by Pfizer for the treatment of ALKpositive or ROS1positive non-small cell lung cancer (NSCLC). The drug was first approved for marketing by the U.S. Food and Drug Administration (FDA) in 2018 and has gradually expanded to other countries and regions, including China.

2.Generic drug manufacturers: In addition to Pfizer’s original drug, there are also generic versions of lorlatinib on the market, mainly produced by pharmaceutical companies in Laos, Bangladesh and other countries. The price of these generic drugs is lower than that of the original drugs, and the ingredients of the drugs are basically the same, providing an alternative option for patients with limited financial conditions.

Pfizer's Lorlatinib is produced in strict accordance with the International Good Manufacturing Practice (GMP) to ensure the safety and efficacy of the drug. Generic drugs need to be certified by local drug regulatory authorities and have the same efficacy and safety as the original drugs.

Larlatinib is developed and produced by Pfizer, and its quality is guaranteed. Generic drugs provide patients with more choices, but when using them, they must be sure to purchase them from regular channels to avoid counterfeit and shoddy products.

xa0

Reference materials

Pfizer official website:https://www.pfizer.com

FDA - Lorlatinib Approval: https://www.fda.gov